# Beijing Jiakesi New Drugs Development Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-jiakesi-new-drugs-development-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.jacobiopharma.com
- Total disclosed funding: $85M
- Latest round: Series C (Feb 1, 2020)
- Investors on record: 9

## About

Established in 2015 and based in Beijing, China, Beijing Jiakesi New Drugs Development Co., Ltd., also known as Jacobio Pharmaceuticals, operates as a biopharmaceutical company that focuses on the research and development of drugs to treat patients with cancer, autoimmune, and infectious diseases.

## Funding rounds

- Series C, Feb 1, 2020, $27M — Qiming Venture Partners, Lilly Asia Ventures, China International Capital Corporation, Hillhouse Investment, Fangyuan Rongtong Fund, Shiyu Capital
- Series C, Aug 30, 2018, $55M — Qiming Venture Partners, Hillhouse Investment, Fangyuan Rongtong Fund
- Series B, Sep 1, 2017, $3.1M — Qiming Venture Partners, Lilly Asia Ventures
- Series A, Oct 22, 2015 — BioEngine Venture Capital, Wisdom Resources Investment Limited, Dazzling Dragon Investment Limited

## Investors

- BioEngine Venture Capital (https://capitalatlas.ai/funds/bioengine-venture-capital) — Series A
- Wisdom Resources Investment Limited — Series A
- Dazzling Dragon Investment Limited — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B, Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series C
- Fangyuan Rongtong Fund (https://capitalatlas.ai/funds/fangyuan-rongtong-fund) — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series C